Search results
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 4 days agoThe adjustment comes in the wake of Merck's first-quarter results, which not only featured a robust...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 5 days agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 6 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows ...
Merck Earnings Preview: Strong quarter expectations on the back of core products' growth
Seeking Alpha· 6 days agoMerck (NYSE:MRK) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 6 days agoModerna stock is yo-yoing after the company unveiled early-stage test results for its...
Merck Raises 2024 Profit Forecast on Strong Sales of Cancer Drug Keytruda
US News & World Report· 5 days agoKeytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing ...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 5 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 5 days agoMerck stock popped Thursday after the Dow Jones stalwart topped Wall Street's first-quarter views on...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
WSAU Wausau· 5 days agoBy Patrick Wingrove (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecast...
Merck and Bristol-Myers Squibb are bracing to lose their most lucrative patents
Quartz· 5 days agoBoth companies reported quarterly earning Thursday, providing insights into how the drug...